Benefits of IL Therapies in Patients with PP


Experts discuss the landscape of IL therapies for the treatment of psoriasis, highlighting their improved safety and efficacy over prior agents.

In this discussion among dermatologists, the focus is on the efficacy and safety of various biologics for treating plaque psoriasis, particularly TNF blockers, IL-23 blockers, and IL-17 blockers. The dermatologists express a preference for newer biologics due to their improved dosing schedules, efficacy, and safety profiles compared to TNF blockers. They highlight the benefits of IL-23 blockers, such as infrequent dosing and favorable safety profiles, especially in patients with comorbidities like inflammatory bowel disease. IL-17 blockers are praised for their rapid improvement in psoriasis symptoms, but concerns arise regarding their efficacy in psoriatic arthritis, particularly in cases of axial involvement. The discussion also touches on the importance of preventing radiographic progression in joint disease and the potential implications for treatment selection. Additionally, the dermatologists discuss the different generations of IL-17 blockers and IL-12/23 blockers, noting advancements in dosing schedules to improve treatment outcomes and patient adherence. Overall, the dermatologists emphasize the importance of considering both efficacy and safety when selecting biologic therapies for plaque psoriasis.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.

Related Videos
Video 2 - "COPD Traits Associated with Phenotypes"
Video 1 - "Why is COPD Important?"
A panel of 4 experts on HIV
A panel of 4 experts on HIV
Video 4 - "Moderate/Severe/Uncontrolled Asthma Classification"
Video 3 - "Type 2 Inflammation and Biomarkers in Asthma"
Video 6 - "Evaluating Safety of Novel LDL Management Mechanism"
Video 5 - "Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data"
© 2024 MJH Life Sciences

All rights reserved.